204 related articles for article (PubMed ID: 15578110)
1. The intangible magic of celebrity marketing.
Moynihan R
PLoS Med; 2004 Nov; 1(2):e42. PubMed ID: 15578110
[TBL] [Abstract][Full Text] [Related]
2. Don't be starstruck by supplements. Celebrity endorsements: who's selling what.
Consum Rep; 2012 Mar; 77(3):12. PubMed ID: 22420061
[No Abstract] [Full Text] [Related]
3. Marketing drugs: debating the real cost. Concern about close ties between doctors and pharmaceutical firms are prompting new financial disclosure laws and education efforts.
Brand R
State Legis; 2008 Sep; 34(8):26-9. PubMed ID: 18754159
[No Abstract] [Full Text] [Related]
4. Medical journals are an extension of the marketing arm of pharmaceutical companies.
Smith R
PLoS Med; 2005 May; 2(5):e138. PubMed ID: 15916457
[TBL] [Abstract][Full Text] [Related]
5. Bold suggestion by Smith.
Cohen D
PLoS Med; 2005 Jul; 2(7):e226. PubMed ID: 16033320
[No Abstract] [Full Text] [Related]
6. Medical journals, academia, and industry-sponsored clinical trials.
Frighi V
PLoS Med; 2005 Jul; 2(7):e218. PubMed ID: 16033312
[No Abstract] [Full Text] [Related]
7. Bitter pills and puffed trials.
Senn S
PLoS Med; 2005 Jul; 2(7):e219; discussion e225. PubMed ID: 16033313
[No Abstract] [Full Text] [Related]
8. PLoS Medicine and the pharmaceutical industry.
PLoS Medicine Editors
PLoS Med; 2006 Jul; 3(7):e329. PubMed ID: 17149970
[TBL] [Abstract][Full Text] [Related]
9. Little fish are less likely to take the bait.
Marcovitch H
PLoS Med; 2005 Jul; 2(7):e221. PubMed ID: 16033315
[No Abstract] [Full Text] [Related]
10. Focus on the funding and production of evidence rather than its publication.
Sheldon T
PLoS Med; 2005 Jul; 2(7):e222. PubMed ID: 16033316
[No Abstract] [Full Text] [Related]
11. Why self-regulation does not work: resolving prescription corruption caused by excessive gift-giving by pharmaceutical manufacturers.
Mehta RS
Food Drug Law J; 2008; 63(4):799-821. PubMed ID: 19593922
[No Abstract] [Full Text] [Related]
12. Pharmaceuticals and medical devices: business practices. End-of-year issue brief.
Jones TM
Issue Brief Health Policy Track Serv; 2008 Jan; ():1-32. PubMed ID: 18345554
[No Abstract] [Full Text] [Related]
13. [Marketing of the LIFE trial anticipates evaluation of the drug].
Järhult B
Lakartidningen; 2002 Apr; 99(17):1964. PubMed ID: 12043424
[No Abstract] [Full Text] [Related]
14. Big pharma and American psychiatry.
Sharfstein SS
J Nerv Ment Dis; 2008 Apr; 196(4):265-6. PubMed ID: 18414119
[No Abstract] [Full Text] [Related]
15. Heartfelt advice, hefty fees: companies pay stars to mention prescription drugs.
Petersen M
N Y Times Web; 2002 Aug; ():Sec 3, 1, 14. PubMed ID: 12391970
[No Abstract] [Full Text] [Related]
16. [Marketing of researchers--lack of judgment or a new trend?].
Werkö L; Hernborg A; Liedholm H; Melander A
Lakartidningen; 2002 Apr; 99(17):1962-3. PubMed ID: 12043423
[No Abstract] [Full Text] [Related]
17. Drug marketing practices criticized.
Wagner L
Mod Healthc; 1990 Dec; 20(50):12. PubMed ID: 10108088
[No Abstract] [Full Text] [Related]
18. Conflicts of interest between physicians and the pharmaceutical industry and special interest groups.
Schetky DH
Child Adolesc Psychiatr Clin N Am; 2008 Jan; 17(1):113-25, ix-x. PubMed ID: 18036482
[TBL] [Abstract][Full Text] [Related]
19. Wyden widens net of probe into drug marketing.
Lehrman S
Nature; 1994 Sep; 371(6492):7. PubMed ID: 8072527
[No Abstract] [Full Text] [Related]
20. Doctors and the drug industry: further thoughts for dealing with potential conflicts of interest?
Alpert JS
Am J Med; 2008 Apr; 121(4):253-5. PubMed ID: 18374678
[No Abstract] [Full Text] [Related]
[Next] [New Search]
